{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:46:06Z","timestamp":1774989966511,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jad.2024.03.057","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T17:10:20Z","timestamp":1710177020000},"page":"206-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Different dosage regimens of zuranolone in the treatment of major depressive disorder: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"354","author":[{"given":"Jinrong","family":"Lian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2024.03.057_bb0005","doi-asserted-by":"crossref","unstructured":"Althaus AL, Ackley MA, Belfort GM, et al. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(A) receptor positive allosteric modulator. Neuropharmacology 2020; 181: 108333. 2020\/09\/26. DOI:https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108333.","DOI":"10.1016\/j.neuropharm.2020.108333"},{"key":"10.1016\/j.jad.2024.03.057_bb0010","doi-asserted-by":"crossref","unstructured":"Boschloo L, Schoevers RA, Beekman AT, et al. The four-year course of major depressive disorder: the role of staging and risk factor determination. Psychother. Psychosom. 2014; 83: 279\u2013288. 2014\/08\/15. DOI:https:\/\/doi.org\/10.1159\/000362563.","DOI":"10.1159\/000362563"},{"key":"10.1016\/j.jad.2024.03.057_bb0015","unstructured":"Chigareva O, Smirnova D, Astafeva D, et al. Comparing the anti-depressive effect of electroconvulsive therapy (ECT) versus transcranial magnetic stimulation (TMS) in the treatment of patients with depression. Psychiatr. Danub 2023; 35: 48\u201355. 2023\/10\/06."},{"key":"10.1016\/j.jad.2024.03.057_bb0020","doi-asserted-by":"crossref","unstructured":"Cipriani A, Koesters M, Furukawa TA, et al. Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst. Rev. 2012; 10: Cd006533. 2012\/10\/19. DOI:https:\/\/doi.org\/10.1002\/14651858.CD006533.pub2.","DOI":"10.1002\/14651858.CD006533.pub2"},{"key":"10.1016\/j.jad.2024.03.057_bb0025","doi-asserted-by":"crossref","unstructured":"Cuijpers P, Quero S, Dowrick C, et al. Psychological treatment of depression in primary care: recent developments. Curr. Psychiatry Rep. 2019; 21: 129. 2019\/11\/25. DOI:https:\/\/doi.org\/10.1007\/s11920-019-1117-x.","DOI":"10.1007\/s11920-019-1117-x"},{"key":"10.1016\/j.jad.2024.03.057_bb0030","doi-asserted-by":"crossref","unstructured":"Cutler AJ, Mattingly GW and Maletic V. Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder. Transl. Psychiatry 2023; 13: 228. 2023\/06\/27. DOI:https:\/\/doi.org\/10.1038\/s41398-023-02514-2.","DOI":"10.1038\/s41398-023-02514-2"},{"key":"10.1016\/j.jad.2024.03.057_bb0035","doi-asserted-by":"crossref","unstructured":"Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al. Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial. JAMA Psychiatry 2021; 78: 951\u2013959. 2021\/07\/01. DOI:https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.1559.","DOI":"10.1001\/jamapsychiatry.2021.1559"},{"key":"10.1016\/j.jad.2024.03.057_bb0040","doi-asserted-by":"crossref","unstructured":"Dwyer JB, Aftab A, Radhakrishnan R, et al. Hormonal treatments for major depressive disorder: state of the art. Am. J. Psychiatry 2020; 177: 686\u2013705. 2020\/05\/28. DOI:https:\/\/doi.org\/10.1176\/appi.ajp.2020.19080848.","DOI":"10.1176\/appi.ajp.2020.19080848"},{"key":"10.1016\/j.jad.2024.03.057_bb0045","doi-asserted-by":"crossref","unstructured":"Dyrbye LN, Thomas MR and Shanafelt TD. Systematic review of depression, anxiety, and other indicators of psychological distress among U.S. and Canadian medical students. Acad. Med. 2006; 81: 354\u2013373. 2006\/03\/28. DOI:https:\/\/doi.org\/10.1097\/00001888-200604000-00009.","DOI":"10.1097\/00001888-200604000-00009"},{"key":"10.1016\/j.jad.2024.03.057_bb0050","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.tips.2018.04.003","article-title":"An emerging circuit pharmacology of GABAA receptors","volume":"39","author":"Engin","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jad.2024.03.057_bb0055","doi-asserted-by":"crossref","unstructured":"Fu YP and Wang Y. Amphetamines abuse and depression: focus on TRPC channels. Exp. Neurol. 2023; 364: 114391. 2023\/03\/31. DOI:https:\/\/doi.org\/10.1016\/j.expneurol.2023.114391.","DOI":"10.1016\/j.expneurol.2023.114391"},{"key":"10.1016\/j.jad.2024.03.057_bb0060","doi-asserted-by":"crossref","unstructured":"Gaebel W, Stricker J and Kerst A. Changes from ICD-10 to ICD-11 and future directions in psychiatric classification.Dialogues Clin. Neurosci. 2020; 22: 7\u201315. 2020\/07\/24. DOI: 10.31887\/DCNS.2020.22.1\/wgaebel.","DOI":"10.31887\/DCNS.2020.22.1\/wgaebel"},{"key":"10.1016\/j.jad.2024.03.057_bb0065","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eplepsyres.2017.05.001","article-title":"Anticonvulsant profile of the neuroactive steroid, SGE-516, in animal models","volume":"134","author":"Hammond","year":"2017","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jad.2024.03.057_bb0070","doi-asserted-by":"crossref","unstructured":"Hawkins NA, Lewis M, Hammond RS, et al. The synthetic neuroactive steroid SGE-516 reduces seizure burden and improves survival in a Dravet syndrome mouse model. Sci. Rep. 2017; 7: 15327. 2017\/11\/12. DOI:https:\/\/doi.org\/10.1038\/s41598-017-15609-w.","DOI":"10.1038\/s41598-017-15609-w"},{"key":"10.1016\/j.jad.2024.03.057_bb0075","doi-asserted-by":"crossref","unstructured":"Hoffmann E, Nomikos GG, Kaul I, et al. SAGE-217, a novel GABA(A) receptor positive allosteric modulator: clinical pharmacology and tolerability in randomized phase I dose-finding studies. Clin. Pharmacokinet. 2020; 59: 111\u2013120. 2019\/07\/25. DOI:https:\/\/doi.org\/10.1007\/s40262-019-00801-0.","DOI":"10.1007\/s40262-019-00801-0"},{"key":"10.1016\/j.jad.2024.03.057_bb0080","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the Management of Adults with major depressive disorder","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jad.2024.03.057_bb0085","doi-asserted-by":"crossref","unstructured":"Kupfer DJ, Frank E and Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 2012; 379: 1045\u20131055. 2011\/12\/23. DOI:https:\/\/doi.org\/10.1016\/S0140-6736(11)60602-8.","DOI":"10.1016\/S0140-6736(11)60602-8"},{"key":"10.1016\/j.jad.2024.03.057_bb0090","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/0706743716659061","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder","volume":"61","author":"Lam","year":"2016","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jad.2024.03.057_bb0095","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1177\/0706743716659416","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder","volume":"61","author":"Lam","year":"2016","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jad.2024.03.057_bb0100","doi-asserted-by":"crossref","unstructured":"Laverty D, Thomas P, Field M, et al. Crystal structures of a GABA(A)-receptor chimera reveal new endogenous neurosteroid-binding sites. Nat. Struct. Mol. Biol. 2017; 24: 977\u2013985. 2017\/10\/03. DOI:https:\/\/doi.org\/10.1038\/nsmb.3477.","DOI":"10.1038\/nsmb.3477"},{"key":"10.1016\/j.jad.2024.03.057_bb0105","doi-asserted-by":"crossref","unstructured":"Lian J, Zhong Y, Li H, et al. Effects of saffron supplementation on improving sleep quality: a meta-analysis of randomized controlled trials. Sleep Med. 2022; 92: 24\u201333. 2022\/03\/25. DOI:https:\/\/doi.org\/10.1016\/j.sleep.2022.03.001.","DOI":"10.1016\/j.sleep.2022.03.001"},{"key":"10.1016\/j.jad.2024.03.057_bb0110","doi-asserted-by":"crossref","unstructured":"Lin HS and Lin CH. Early improvement in HAMD-17 and HAMD-6 scores predicts ultimate response and remission for depressed patients treated with fluoxetine or ECT. J. Affect. Disord. 2019; 245: 91\u201397. 2018\/10\/28. DOI:https:\/\/doi.org\/10.1016\/j.jad.2018.10.105.","DOI":"10.1016\/j.jad.2018.10.105"},{"key":"10.1016\/j.jad.2024.03.057_bb0115","doi-asserted-by":"crossref","unstructured":"Locskai LF, Alyenbaawi H and Allison WT. Antiepileptic drugs as potential dementia prophylactics following traumatic brain injury. Annu. Rev. Pharmacol. Toxicol. 2023 2023\/10\/03. DOI:https:\/\/doi.org\/10.1146\/annurev-pharmtox-051921-013930.","DOI":"10.1146\/annurev-pharmtox-051921-013930"},{"key":"10.1016\/j.jad.2024.03.057_bb0120","doi-asserted-by":"crossref","unstructured":"McIntyre RS, Zimmerman M, Goldberg JF, et al. Differential diagnosis of major depressive disorder versus bipolar disorder: current status and best clinical practices. J. Clin. Psychiatry 2019; 80 2019\/05\/16. DOI:https:\/\/doi.org\/10.4088\/JCP.ot18043ah2.","DOI":"10.4088\/JCP.ot18043ah2"},{"key":"10.1016\/j.jad.2024.03.057_bb0125","doi-asserted-by":"crossref","unstructured":"Mel\u00f3n L, Hammond R, Lewis M, et al. A novel, synthetic, neuroactive steroid is effective at decreasing depression-like behaviors and improving maternal care in preclinical models of postpartum depression. Front. Endocrinol. (Lausanne) 2018; 9: 703. 2018\/12\/12. DOI:https:\/\/doi.org\/10.3389\/fendo.2018.00703.","DOI":"10.3389\/fendo.2018.00703"},{"key":"10.1016\/j.jad.2024.03.057_bb0130","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0140-6736(18)31551-4","article-title":"Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"392","author":"Meltzer-Brody","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2024.03.057_bb0135","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1177\/0706743716660033","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder","volume":"61","author":"Milev","year":"2016","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jad.2024.03.057_bb0140","doi-asserted-by":"crossref","unstructured":"Mirza I and Jenkins R. Risk factors, prevalence, and treatment of anxiety and depressive disorders in Pakistan: systematic review. Bmj 2004; 328: 794. 2004\/04\/09. DOI:https:\/\/doi.org\/10.1136\/bmj.328.7443.794.","DOI":"10.1136\/bmj.328.7443.794"},{"key":"10.1016\/j.jad.2024.03.057_bb0145","doi-asserted-by":"crossref","unstructured":"Monroe SM and Harkness KL. Major depression and its recurrences: life course matters. Annu. Rev. Clin. Psychol. 2022; 18: 329\u2013357. 2022\/02\/27. DOI:https:\/\/doi.org\/10.1146\/annurev-clinpsy-072220-021440.","DOI":"10.1146\/annurev-clinpsy-072220-021440"},{"key":"10.1016\/j.jad.2024.03.057_bb0150","doi-asserted-by":"crossref","unstructured":"Nuss P. Anxiety disorders and GABA neurotransmission: a disturbance of modulation. Neuropsychiatr. Dis. Treat. 2015; 11: 165\u2013175. 2015\/02\/06. DOI:https:\/\/doi.org\/10.2147\/ndt.S58841.","DOI":"10.2147\/NDT.S58841"},{"key":"10.1016\/j.jad.2024.03.057_bb0155","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/0706743716659418","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder","volume":"61","author":"Parikh","year":"2016","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jad.2024.03.057_bb0160","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41386-023-01751-9","article-title":"Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study","volume":"49","author":"Parikh","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2024.03.057_bb0165","doi-asserted-by":"crossref","unstructured":"Patterson R, Balan I, Morrow AL, et al. Novel neurosteroid therapeutics for post-partum depression: perspectives on clinical trials, program development, active research, and future directions. Neuropsychopharmacology 2023 2023\/09\/16. DOI:https:\/\/doi.org\/10.1038\/s41386-023-01721-1.","DOI":"10.1038\/s41386-023-01721-1"},{"key":"10.1016\/j.jad.2024.03.057_bb0170","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/0706743716660290","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder","volume":"61","author":"Ravindran","year":"2016","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jad.2024.03.057_bb0175","doi-asserted-by":"crossref","unstructured":"Rybak YE, Lai KSP, Ramasubbu R, et al. Treatment-resistant major depressive disorder: Canadian expert consensus on definition and assessment. Depress Anxiety 2021; 38: 456\u2013467. 2021\/02\/03. DOI:https:\/\/doi.org\/10.1002\/da.23135.","DOI":"10.1002\/da.23135"},{"key":"10.1016\/j.jad.2024.03.057_bb0180","doi-asserted-by":"crossref","unstructured":"Sanchez C, Reines EH and Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? Int. Clin. Psychopharmacol. 2014; 29: 185\u2013196. 2014\/01\/16. DOI:https:\/\/doi.org\/10.1097\/yic.0000000000000023.","DOI":"10.1097\/YIC.0000000000000023"},{"key":"10.1016\/j.jad.2024.03.057_bb0185","doi-asserted-by":"crossref","unstructured":"Schramm E, Klein DN, Elsaesser M, et al. Review of dysthymia and persistent depressive disorder: history, correlates, and clinical implications. Lancet Psychiatry 2020; 7: 801\u2013812. 2020\/08\/24. DOI:https:\/\/doi.org\/10.1016\/S2215-0366(20)30099-7.","DOI":"10.1016\/S2215-0366(20)30099-7"},{"key":"10.1016\/j.jad.2024.03.057_bb0190","doi-asserted-by":"crossref","unstructured":"Sear JW. Steroid anesthetics: old compounds, new drugs. J. Clin. Anesth. 1996; 8: 91s\u201398s. 1996\/05\/01. DOI:https:\/\/doi.org\/10.1016\/s0952-8180(96)90021-5.","DOI":"10.1016\/S0952-8180(96)90021-5"},{"key":"10.1016\/j.jad.2024.03.057_bb0195","doi-asserted-by":"crossref","unstructured":"Tossell K, Yu X, Giannos P, et al. Somatostatin neurons in prefrontal cortex initiate sleep-preparatory behavior and sleep via the preoptic and lateral hypothalamus. Nat. Neurosci. 2023; 26: 1805\u20131819. 2023\/09\/22. DOI:https:\/\/doi.org\/10.1038\/s41593-023-01430-4.","DOI":"10.1038\/s41593-023-01430-4"},{"key":"10.1016\/j.jad.2024.03.057_bb0200","doi-asserted-by":"crossref","unstructured":"Uchida S, Yamagata H, Seki T, et al. Epigenetic mechanisms of major depression: targeting neuronal plasticity. Psychiatry Clin. Neurosci. 2018; 72: 212\u2013227. 2017\/11\/21. DOI:https:\/\/doi.org\/10.1111\/pcn.12621.","DOI":"10.1111\/pcn.12621"},{"key":"10.1016\/j.jad.2024.03.057_bb3000","unstructured":"WHO, Depressive disorder (depression), 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression. (Accessed 03-31 2023)."},{"key":"10.1016\/j.jad.2024.03.057_bb0205","doi-asserted-by":"crossref","unstructured":"Zugman A, Jett L, Antonacci C, et al. A systematic review and meta-analysis of resting-state fMRI in anxiety disorders: need for data sharing to move the field forward. J. Anxiety Disord. 2023; 99: 102773. 2023\/09\/24. DOI:https:\/\/doi.org\/10.1016\/j.janxdis.2023.102773.","DOI":"10.1016\/j.janxdis.2023.102773"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724004725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724004725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T21:20:27Z","timestamp":1737408027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724004725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":42,"alternative-id":["S0165032724004725"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.03.057","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Different dosage regimens of zuranolone in the treatment of major depressive disorder: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.03.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}